DK1048653T3 - Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf - Google Patents

Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf

Info

Publication number
DK1048653T3
DK1048653T3 DK98956013T DK98956013T DK1048653T3 DK 1048653 T3 DK1048653 T3 DK 1048653T3 DK 98956013 T DK98956013 T DK 98956013T DK 98956013 T DK98956013 T DK 98956013T DK 1048653 T3 DK1048653 T3 DK 1048653T3
Authority
DK
Denmark
Prior art keywords
donepezil
polycrystals
preparation
producing
handleability
Prior art date
Application number
DK98956013T
Other languages
Danish (da)
English (en)
Inventor
Akio Imai
Toshiyuki Ichinohe
Takashi Endo
Tomio Tsurugi
Makoto Uemura
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18296352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1048653(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK1048653T3 publication Critical patent/DK1048653T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Hydrogenated Pyridines (AREA)
DK98956013T 1997-12-05 1998-12-01 Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf DK1048653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33616597 1997-12-05
PCT/JP1998/005405 WO1999029668A1 (fr) 1997-12-05 1998-12-01 Polycristaux de donepezil et leur procede de production

Publications (1)

Publication Number Publication Date
DK1048653T3 true DK1048653T3 (da) 2004-05-24

Family

ID=18296352

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98956013T DK1048653T3 (da) 1997-12-05 1998-12-01 Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf

Country Status (8)

Country Link
US (1) US6245911B1 (fr)
EP (1) EP1048653B1 (fr)
AT (1) ATE260896T1 (fr)
DE (1) DE69822218T2 (fr)
DK (1) DK1048653T3 (fr)
ES (1) ES2218869T3 (fr)
PT (1) PT1048653E (fr)
WO (1) WO1999029668A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
EP2133078A1 (fr) 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Utilisation d'un inhibiteur de la cholinestérase pour le traitement de troubles cognitifs et/ou d'une démence associés à ou provoqués par des tumeurs cérébrales
WO2001078721A1 (fr) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Agents de reduction de a$g(b)42
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
US7439365B2 (en) * 2003-11-17 2008-10-21 Usv, Ltd. Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
AU2003230195A1 (en) * 2003-04-02 2004-10-25 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
EP1776089A2 (fr) * 2003-12-31 2007-04-25 Actavis Group hf Formulations de donepezil
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1745180A1 (fr) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Placages pour parois, murs de soutenement et analogues
AU2005244867A1 (en) * 2004-05-14 2005-12-01 The Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
EP1773339A4 (fr) * 2004-07-30 2009-07-29 Reddys Lab Ltd Dr Forme cristalline d'hydrochlorure de donepezil
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
KR20070083679A (ko) * 2004-09-29 2007-08-24 케마지스 리미티드 약학적으로 순수한 비정질 도네페닐 염산염의 제조를 위한정제된 도네페질 말레산염의 용도
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
DE602005016009D1 (de) * 2004-11-23 2009-09-24 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure-derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US20060122226A1 (en) * 2004-12-08 2006-06-08 Itai Adin Crystalline forms of Donepezil base
JP2008537552A (ja) * 2005-04-04 2008-09-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ジヒドロピリジン化合物および頭痛用組成物
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
ZA200801825B (en) * 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
WO2007018801A1 (fr) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Compositions de donépézil gélifié et procédés pour les fabriquer et les utiliser
WO2007108011A2 (fr) * 2006-03-20 2007-09-27 Ind-Swift Laboratories Limited Procede de preparation de donepezile de grande purete
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
JP5097359B2 (ja) * 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
WO2008050351A1 (fr) * 2006-10-25 2008-05-02 Jubilant Organosys Limited Nouvelles formes polymorphes de la 1-benzyl-4-[(5,6-diméthoxy-1-indanon)-2-yl]méthylpipéridine [donépézil] et procédé servant à préparer celles-ci
SG178000A1 (en) 2006-10-27 2012-02-28 Medivation Neurology Inc Methods and combination therapies for treating alzheimer's disease
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20100099714A1 (en) * 2007-03-05 2010-04-22 Eisai R&D Management Co., Ltd. AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
WO2008139984A1 (fr) * 2007-04-26 2008-11-20 Eisai R & D Management Co., Ltd. Composés de cinnamide destinés au traitement de la démence
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
JP5562337B2 (ja) * 2008-12-17 2014-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ドネペジルの多形結晶及びその製造方法
AU2011215870B2 (en) * 2010-02-09 2016-01-28 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2366378A1 (fr) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Formulations de donépézil à libération prolongée
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
WO2012053016A1 (fr) 2010-10-22 2012-04-26 Cadila Healthcare Limited Compositions pharmaceutiques de donépézil à libération prolongée
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
WO2014144801A1 (fr) 2013-03-15 2014-09-18 Agenebio Inc. Procédés et compositions pour améliorer la fonction cognitive
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
JP6619027B2 (ja) 2015-05-08 2019-12-11 ダウ グローバル テクノロジーズ エルエルシー アゾジカルボンアミド／クエン酸塩混合物を核剤として使用してポリオレフィン組成物を発泡させる方法
NZ776101A (en) 2015-05-22 2024-10-25 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
KR102649060B1 (ko) 2017-10-06 2024-03-20 렌징 악티엔게젤샤프트 필라멘트의 압출 및 스펀본디드 패브릭의 제조를 위한 장치
BR112021022300A2 (pt) 2019-05-17 2021-12-28 Chemiefaser Lenzing Ag Método e dispositivo para limpeza de fieira durante a produção de não tecido celulósico de filamento contínuo (spunbond)
CN112939846B (zh) * 2019-11-26 2023-12-26 中国科学院上海药物研究所 一种乙酰胆碱酯酶抑制剂的晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
CA2252806C (fr) 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphes de chlorhydrate de donepezil, et leur procede de production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride

Also Published As

Publication number Publication date
ATE260896T1 (de) 2004-03-15
ES2218869T3 (es) 2004-11-16
EP1048653B1 (fr) 2004-03-03
US6245911B1 (en) 2001-06-12
PT1048653E (pt) 2004-07-30
EP1048653A4 (fr) 2001-03-07
WO1999029668A1 (fr) 1999-06-17
DE69822218T2 (de) 2005-02-03
DE69822218D1 (de) 2004-04-08
EP1048653A1 (fr) 2000-11-02

Similar Documents

Publication Publication Date Title
DK1048653T3 (da) Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf
DK0618209T3 (da) Pyridothiadiaziner, fremgangsmåder til fremstilling heraf og farmaceutiske sammensætninger indeholdende dem
NO941678D0 (no) nor-gallesyrederivater, fremgangsmåte for fremstilling og anvendelse av dem som legemiddel
ES2100136T3 (es) Omeprazol de magnesio.
EP0571217A3 (en) Novel simethicone containing pharmaceutical compositions for treating gastrointestinal distress
DK0506539T3 (da) heterocykliske alkylamider, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
GB8801306D0 (en) Chemical compounds
DE59000750D1 (de) Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate.
NO933200D0 (no) Substituerte cykloheksanderivater, fremgangsm}te til fremstilling derav og anvendelsen av forbindelsene til behandling av sykdommer
DK568989A (da) Fremgangsmaade til fremstilling af 3,5-dimethyl-4-methoxypyridin-derivater og mellemprodukter til brug ved fremgangsmaaden
NO305554B1 (no) Nye bis-naftalimider og farmas°ytisk blanding for behandling av kreft
HUT74768A (en) 1-amino-3-phenyluracil derivatives, preparation thereof, using thereof as herbicides, desiccants and defoliants, such compositions and process for the production of the latters
DK0564358T3 (da) 3-aminochroman-spiro-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende sådanne
ATA168395A (de) Neue kristallform von morphin-6-glucuronid
EP0457090A3 (en) Process for the preparation of 3-amino-2 (het)aroyl-acrylic acid derivatives
GR3033099T3 (en) Process for the preparation of 7-(3-amino- and 3-aminomethyl-1-pyrrolidinyl)-3-quinolinonecarboxylic and -naphthyridinonecarboxylic acids.
ZA942964B (en) Pyrrolopyrazine compounds processes for their preparation and the pharmaceutical compositions which contain them
DK1001961T3 (da) Substituerede derivater af tetrahydrofuran og fremgangsmåde til deres fremstilling
ATE374028T1 (de) Kristallines isoxazol-derivat und medizinisches präparat daraus
NO304025B1 (no) Heteroarenylpiperaziner, farmas°ytiske preparater inneholdende slike forbindelser og anvendelse derav som legemidler
IL88914A0 (en) Ketenedithioacetal derivatives,processes for producing the same and pharmaceutical compositions containing the same